Sökning: onr:"swepub:oai:gup.ub.gu.se/273700" >
Serum neurofilament...
Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer's disease
-
Sanchez-Valle, R. (författare)
-
Heslegrave, A. (författare)
-
Foiani, M. S. (författare)
-
visa fler...
-
Bosch, B. (författare)
-
Antonell, A. (författare)
-
Balasa, M. (författare)
-
Llado, A. (författare)
-
- Zetterberg, Henrik, 1973 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
Fox, N. C. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2018-11-03
- 2018
- Engelska.
-
Ingår i: Alzheimers Research & Therapy. - : Springer Science and Business Media LLC. - 1758-9193. ; 10
- Relaterad länk:
-
https://alzres.biome...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BackgroundBiomarkers that can track disease onset and progression in autosomal dominant Alzheimer's disease (ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with clinical and cerebrospinal fluid (CSF) markers in ADAD. We also evaluate serum NfL differences between clinical groups.MethodsSerum NfL was measured cross-sectionally in 60 individuals from ADAD families using an ultrasensitive immunoassay on the Single molecule array (Simoa) platform and longitudinally in an exploratory study in a subset of six mutation carriers. Spearman coefficients assessed associations between serum NfL and relevant measures. Differences between groups were evaluated by Kruskal-Wallis and Mann-Whitney U tests.ResultsForty-two participants were mutation carriers: 22 symptomatic (SMC) and 20 asymptomatic (AMC). Eighteen subjects were non-carriers and cognitively normal (controls (CTR)). Serum NfL correlated with the estimated years from symptoms onset across mutation carriers (rho=0.75, p<0.001). In mutation carriers, serum NfL also showed strong correlation with clinical (rho=0.70, p<0.001) and cognitive (rho=-0.77, p<0.001) measures and CSF NfL, total tau and phosphorylated tau levels (rho=0.72, 0.71, and 0.71, respectively, all p<0.001). Serum NfL concentration was higher in SMC than in AMC and CTR.ConclusionsSerum NfL might be a feasible non-invasive biomarker to track disease onset and severity in ADAD.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Nyckelord
- Alzheimer's disease
- Biomarkers
- Familial Alzheimer's disease
- Presenilin 1
- Neurofilament light
- amyotrophic-lateral-sclerosis
- frontotemporal dementia
- biomarker
- chain
- association
- protein
- trials
- Neurosciences & Neurology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas